MaR1 reduces inflammation by reducing neutrophil and macrophage infiltration, activating Nrf2 signalling, and inactivating TLR4/NF-κB signalling. Besides, MaR1 improves TJ protein expression and decreases MPO and ROS activity, therefore ameliorating DSS-induced colitis. The gene discussed is TLR4; the disease is colitis.